Verdiva Bio Launches with $410M in Financing for Groundbreaking Therapies

Verdiva Bio, a newly launched clinical-stage biopharmaceutical company, has announced its emergence with an impressive $410M Series A financing round. Co-founded by Khurem Farooq, the company is aiming to develop next-generation therapies for obesity and cardiometabolic disorders. With its innovative portfolio of oral and injectable treatments, Verdiva is set to transform patient care with therapies that offer improved efficacy and tolerability. The financing round was co-led by Forbion and General Atlantic, with participation from several other prominent investors, highlighting significant interest in Verdiva's potential. The company is poised to leverage its proprietary oral delivery technology to offer patient-friendly treatments, thereby enhancing both access and affordability. Verdiva Bio has acquired global rights from Sciwind Biosciences, except in China and South Korea, for its leading assets, which include a once-weekly oral GLP-1 receptor agonist in phase 2 readiness, among others. The leadership team, comprised of industry veterans and previously part of Aiolos Bio and Gyroscope Therapeutics, brings a wealth of experience. Verdiva Bio's proactive approach in advancing therapies through a mix of monotherapy and combination programs positions it as a key innovator in the landscape of weight management and metabolic health.